REGENXBIO Inc. (RGNX)
NASDAQ: RGNX · Real-Time Price · USD
9.01
+0.19 (2.15%)
At close: Aug 28, 2025, 4:00 PM
9.02
+0.01 (0.11%)
After-hours: Aug 28, 2025, 7:14 PM EDT
REGENXBIO Employees
REGENXBIO had 353 employees as of December 31, 2024. The number of employees increased by 9 or 2.62% compared to the previous year.
Employees
353
Change (1Y)
9
Growth (1Y)
2.62%
Revenue / Employee
$441,309
Profits / Employee
-$497,368
Market Cap
455.13M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 353 | 9 | 2.62% |
Dec 31, 2023 | 344 | -57 | -14.21% |
Dec 31, 2022 | 401 | 29 | 7.80% |
Dec 31, 2021 | 372 | 66 | 21.57% |
Dec 31, 2020 | 306 | 49 | 19.07% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
RGNX News
- 18 hours ago - REGENXBIO to Participate in Upcoming Investor Conferences - PRNewsWire
- 9 days ago - FDA Extends Decision Date On Regenxbio's Gene Therapy Into Next Year - Benzinga
- 10 days ago - REGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS II - PRNewsWire
- 20 days ago - REGENXBIO Inc. (RGNX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 21 days ago - REGENXBIO Reports Second Quarter 2025 Financial Results and Operational Highlights - PRNewsWire
- 21 days ago - REGENXBIO Announces Pivotal Program for Surabgene Lomparvovec in Diabetic Retinopathy - PRNewsWire
- 4 weeks ago - REGENXBIO to Host Conference Call on August 7 to Discuss Second Quarter 2025 Financial Results and Operational Highlights - PRNewsWire
- 7 weeks ago - REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy - PRNewsWire